Format:
Online-Ressource
ISSN:
1423-0291
Content:
Introduction: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms. Methods: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Results: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92–99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p 〈 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p 〈 0.0001 each), and reduced survival (p = 0.03). Conclusion: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.
In:
volume:90
In:
number:4
In:
year:2023
In:
pages:219-232
In:
extent:14
In:
Pathobiology, Basel : Karger, 1938-, 90, Heft 4 (2023), 219-232 (gesamt 14), 1423-0291
Language:
English
URN:
urn:nbn:de:101:1-2023081700395265769235
URL:
https://doi.org/10.1159/000527382
URL:
https://nbn-resolving.org/urn:nbn:de:101:1-2023081700395265769235
URL:
https://d-nb.info/1299451381/34
URL:
https://karger.com/pat/article-pdf/90/4/219/3983714/000527382.pdf
URL:
https://karger.com/doi/10.1159/000527382
Bookmarklink